<DOC>
	<DOCNO>NCT01329991</DOCNO>
	<brief_summary>PLX115-02 phase 1b study ass study drug , PLX5622 : 1. affect body , 2. body affect PLX5622 3. interaction PLX5622 Methotrexate 4. safety PLX5622 rheumatoid arthritis patient take Methotrexate</brief_summary>
	<brief_title>Phase 1b Study PLX5622 Rheumatoid Arthritis Patients Who Are Receiving Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Male female patient ≥ 18 year old diagnosis rheumatoid arthritis ACR criterion ≥ 3 month . Prior Day 1 , patient must oral subcutaneous methotrexate ( ≥10 mg/week ≤ 25 mg/week ) least 12 week ( stable dose least 4 week ) folate ( ≥ 5 mg/week ) least 6 week , willing continue regimen duration study . Adequate hematologic , hepatic , renal function ( absolute neutrophil count ≥ 1.5 X 109/L , Hgb &gt; 9 g/dL , platelet count ≥ 100 X 109/L , AST/ALT WNL , albumin ≥ 3 g/dL , calculate CrCl &gt; 60 mL/min use CockcroftGault formula ) . Women childbearing potential must negative pregnancy test within 7 day prior initiation dose study drug must agree use double barrier method birth control time negative pregnancy test 30 day last dose study drug . Women nonchildbearing potential may include either surgically sterile postmenopausal ≥ 1 year . Fertile men must agree use acceptable method birth control study drug . Acceptable method contraception must include either abstinence first dose study drug 4 week last dose study drug , use condom instruction female partner childbearing potential also protect . Willing able provide write informed consent prior studyrelated procedure comply study requirement . Use biologic response modifier within follow period prior Day 1 : 4 week Kineret ( anakinra ) Enbrel ( etanercept ) ; 12 week Remicade ( infliximab ) , Humira ( adalimumab ) , Simponi ( golimumab ) , Orencia ( abatacept ) , Actemra ( tocilizumab ) , Cimzia ( certolizumab ) ; 12 month Rituxan ( rituximab ) . Use Arava ( leflunomide ) within 12 week prior Day 1 immunosuppressive agent , include hydroxychloroquine sulfasalazine , within 4 week Day 1 . Investigational drug use within 4 week Day 1 . Positive urine drug screen drug abuse ( except opiate use RA ) . Concomitant use DMARDs ( methotrexate ) , biological response modifier , know strong inducer inhibitor CYP3A4 ( see Appendix 2 ) . Uncontrolled intercurrent illness . Refractory nausea vomiting , malabsorption , external biliary shunt , significant bowel resection would preclude adequate absorption . QTc ≥ 450 msec Screening . The presence medical psychiatric condition , opinion Principal Investigator , make patient inappropriate inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>RA</keyword>
	<keyword>Methotrexate</keyword>
</DOC>